# Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

> **NCT01968265** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ISIS-GCCRRx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01968265
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-01
- **Final completion:** 2015-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968265, "Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01968265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*